Vortioxetine attenuates rotenone-induced enteric neuroinflammation via modulation of the TLR2/S100B/RAGE signaling pathway in a rat model of Parkinson's disease.

Summary: A Gut Check for Parkinson’s: Can an Antidepressant Help?

We often think of Parkinson’s disease as a brain disorder affecting movement, but emerging research suggests it may actually start in the gut. Pathological changes in the enteric nervous system—the "second brain" in our digestive tract—often appear long before tremors set in.

In a new study, researchers investigated whether Vortioxetine, a medication commonly prescribed for depression, could protect the gut from Parkinson’s-related damage. Using a rat model exposed to Rotenone (a toxin that mimics Parkinson’s effects), they found that the drug did more than just regulate mood. Vortioxetine significantly reduced inflammation in the gut’s glial cells and lowered the accumulation of harmful proteins like alpha-synuclein. By modulating specific signaling pathways (TLR2/S100B/RAGE), this antidepressant acted as a shield, dampening the neuroinflammation that drives the disease. This offers a promising hint that treating the gut might one day help slow the progression of Parkinson’s.